

1 THE COURT: YOU MAY PROCEED.

2 MR. PASAHOW: YOUR HONOR, PERHAPS I SHOULD BEGIN BY
3 INTRODUCING OUR ADDITION TO COUNSEL TABLE AS WELL. THE
4 GENTLEMEN AT THE END OF OUR COUNSEL TABLE IS DR. KARY MULLIS.

5 THE COURT: THANK YOU.

6 MR. PASAHOW: LADIES AND GENTLEMEN, IN THE SPRING OF
7 1983, THE EXACT DATE IS NOT KNOWN, DR. KARY MULLIS BEGAN A TRIP
8 UP HIGHWAY 101 TO A CABIN HE RENTED IN MENDOCINO. THE TRIP
9 PROVED TO BE A VERY IMPORTANT ONE, BOTH FOR DR. MULLIS
10 PERSONALLY AND BIOTECHNOLOGY BECAUSE IT WAS ON THAT TRIP THAT
11 DR. MULLIS INVENTED THE TECHNIQUE THAT'S KNOWN AS
12 POLYMERASE CHAIN REACTION.

13 AFTER DR. MULLIS RETURNED TO CETUS AND REDUCED THE
14 INVENTION THAT HE THOUGHT OF DURING THAT TRIP TO A METHOD HE
15 COULD SHOW OTHER HE WORKED WITH, HIS COLLEAGUES, TO INVENT
16 VARIOUS APPLICATIONS OF THAT TECHNIQUE. SOME OF THOSE VERY
17 IMPORTANT APPLICATIONS WERE USING IT TO DETECT DISEASES,
18 DISEASES THAT INFLICT HUMANS.

19 IN PARTICULAR DISEASES THAT ARE KNOWN AS GENTIC
20 DISEASE. GENTIC DISEASES ARE CAUSED BY ERRORS IN OUR DNA, IN
21 OUR GENES ONE OF THOSE FOUR BASIS MR. FIGG POINTED OUT SOMETIMES
22 ARE WRONG. IF ONE OF THE FOUR BASIS IS WRONG WE CAN SUFFER
23 VARIOUS DISEASES.

24 THE CETUS SCIENTISTS WE'RE LOOKING FOR A PRACTICAL,
25 SIMPLE WAY TO MAKE IT POSSIBLE FOR DOCTORS AND HOSPITALS TO

1 DETECT THOSE GENTIC DISEASES. THAT IS WHAT IS THE SUBJECT
2 MATTER OF ONE OF THE TWO PATENTS.

3 CETUS' EVIDENCE WILL SHOW YOU THAT THE UNITED STATES
4 PATENT AND TRADEMARK OFFICE PROPERLY UNDER THE LAW ISSUED
5 PATENTS TO CETUS FOR THE WORK ITS SCIENTISTS DID IN INVENTING
6 PCR AND IN INVENTING THESE VERY IMPORTANT APPLICATIONS OF THE
7 REVOLUTIONARY PCR TECHNIQUE.

8 INDEED YOU'LL SEE THAT'S EXACTLY THE CONCLUSION THE
9 PATENT OFFICE ITSELF CAME TO LAST YEAR WHEN DU PONT TOOK ALL THE
10 ARGUMENTS IT WANTED TO TAKE TO THE PATENT OFFICE AND ASKED THE
11 EXPERTS THERE TO RE-EXAMINE THE PATENTS AND SEE IF THEY MADE A
12 MISTAKE IN THE FIRST PLACE WHEN THEY ALLOWED THE PATENTS IN
13 1967.

14 YOU'LL SEE THAT FOLLOWING CONSIDERATION OF THE
15 ARGUMENTS DU PONT CHOSE TO MAKE -- REVIEWING THE PRINTED
16 PUBLICATIONS THAT DU PONT CHOSE TO PUT BEFORE THE PATENT OFFICE,
17 THE EXPERTS IN THE PATENT OFFICE CONCLUDED THE PATENTS WERE
18 PROPERLY ISSUED IN 1987. SO THEY REAFFIRMED EACH AND EVERY ONE
19 OF THE CLAIMS IN BOTH OF THE TWO PATENTS.

20 NOW, BEFORE DR. MULLIS CAME TO WORK AT CETUS'
21 EMERYVILLE LABORATORY, HE HAD GONE THROUGH THE USUAL COURSE OF
22 STUDY OF A BIOCHEMIST. FIRST, HE HAD SPENT THE TIME GETTING A
23 PHD DEGREE AT THE UNIVERSITY OF CALIFORNIA AT BERKLEY, STUDYING
24 SEVERAL YEARS THERE, AND THEN LIKE MANY BIOCHEMISTS HE FOLLOWED
25 THAT UP WITH A POST-DOCTORAL RESEARCH PROGRAM. IN HIS CASE HE

2
1 SPENT SEVERAL YEARS WORKING WITH A MORE SENIOR SCIENTISTS AT THE
2 UNIVERSITY OF CALIFORNIA HERE IN SAN FRANCISCO.

3 AFTER THAT DR. MULLIS WAS HIRED BY CETUS. IN 1983 THE
4 FOCUS OF DR. MULLIS' WORK WAS MAKING THE SHORT PIECES OF DNA
5 THAT WERE USED AS PRIMERS AND PROBES BY OTHER SCIENTISTS IN THE
6 CETUS LABORATORY.

7 BUT YOU'LL HEAR THAT DR. MULLIS HAD CREATED A
8 LABORATORY THAT WAS SO EFFICIENT AT THAT PROCESS, THAT HE HAD
9 EXTRA TIME ON HIS HANDS AND HE CHOSE TO USE THAT EXTRA TIME,
10 WITH THE CONCURRENCE OF HIS SUPERVISORS, TO HELP OTHER
11 SCIENTISTS WITH ROAD BLOCKS THEY WERE HAVING IN WORK THEY WERE
12 DOING.

13 IN EARLY 1983 THE PROJECT THAT CAUGHT DOCTOR MULLIS'
14 ATTENTION, IN ADDITION TO THE MAKING OF THESE DNA PIECES, WAS
15 WORK THAT WAS GOING ON IN THE LABORATORY OF DOCTOR HENRY ERLICH
16 THE SAME HAVE RESPECTED SCIENTIST THAT MR. FIGG SPOKE OF.

17 YOU'LL HEAR DOCTOR ERLICH'S LABORATORY WAS FOCUSING ON
18 COMING UP WITH A PRACTICAL SIMPLE METHOD OF DETECTING GENETIC
19 DISEASES, ONE THAT COULD BE USED BY DOCTORS AND HOSPITALS AND
20 DIDN'T REQUIRE A HEAVILY TRAINED BIOCHEMIST OR
21 MOLECULARBIOLOGIST.

22 YOU'LL HEAR IN 1983 FROM TIME TO TIME DOCTOR MULLIS
23 DISCUSSED THE WORK GOING ON IN THAT LABORATORY WITH THE
24 SCIENTISTS THERE. YOU'LL HEAR THAT HE SUGGESTED IDEAS TO THEM
25 AND HE DISCUSSED THEIR WORK WITH THEM.

2
1 YOU'LL HEAR THAT HE, AS HE TOOK THAT DRIVE UP 101 TO
2 THE CABIN IN MENDOCINO THAT DAY, HIS THOUGHTS WERE ON THIS
3 PROBLEM THAT WERE PLAGUING THE CETUS SCIENTISTS AT WORK. THE
4 PROBLEM HOW DO YOU MAKE THE TEST MORE SENSITIVE. HOW DO YOU
5 MAKE IT SO IT CAN BE SIMPLY USED, USED BY PEOPLE WHO ARE NOT
6 TRAINED LABORATORY BIOCHEMIST AND MOLECULARBIOLOGIST.

7 THE SOLUTION DR. MULLIS THOUGHT OF IS WHAT'S NOW KNOWN
8 AS POLYMERASE CHAIN REACTION. YOU'LL HEAR DR. MULLIS WAS VERY
9 EXCITED ABOUT HIS THOUGHTS EVEN THAT WEEKEND. HE CAME BACK TO
10 THE EMERYVILLE LABORATORY THE NEXT MONDAY AND THE FIRST THING HE
11 DID WAS ASK THAT A LITERATURE SEARCH BE DONE WITH A COMPUTER BY
12 THE LIBRARIAN AT CETUS. HE WANTED TO FIND OUT IF ANYONE ELSE
13 HAD EVER TRIED THIS IDEA BEFORE.

14 THE RESULT CAME BACK TO HIM. HE LOOKED THROUGH THE
15 RESULTS OF THE SEARCH. HE CONCLUDED, NO, NO ONE ELSE HAD TRIED
16 IT BEFORE. SO THEN DR. MULLIS BEGAN RESEARCHING HOW ONE MIGHT
17 ACTUALLY GO ABOUT DOING THIS.

18 NOW, A LOT OF RESEARCH HAD TO BE DONE BEFORE HE COULD
19 EVEN TRY THE FIRST EXPERIMENT. HE HAD TO FIGURE OUT WHAT
20 CHEMICALS TO PUT IN; HOW MANY POLYMERASE; WHAT POLYMERASE. HE
21 HAD TO FIGURE OUT HOW MUCH OF THE TARGET, THAT IS, THE TEMPLATE
22 DNA HE WAS DRYING TO COPY.

23 HE HAD TO FIGURE OUT HOW MANY PRIMERS AND WHAT THE
24 RELATIVE CONCENTRATIONS OF ALL OF THESE THINGS SHOULD BE. HE
25 HAD TO FIGURE OUT THE TIMES AND TEMPERATURES FOR RUNNING THE

3
1 REACTION.

2 DR. MULLIS RESEARCHED ARTICLES BY OTHERS WHO HAD DONE
3 THINGS WHICH HE THOUGHT MIGHT GIVE CLUES FOR HIS REACTION AND HE
4 DID CALCULATIONS AND HE DID SOME EXPERIMENTS, AND FINALLY IN
5 SEPTEMBER 1983 HE WAS READY TO TRY HIS FIRST EXPERIMENT. AND
6 YOU'LL HEAR FROM DR. MULLIS THAT THAT FIRST EXPERIMENT WAS JUST
7 PLAINLY A FAILURE. THERE WAS NO INDICATION AT ALL THAT THE
8 PROCESS WORKED.

9 SO DR. MULLIS WENT BACK TO THE DRAWING BOARD, IF YOU
10 WILL, AND HE CHANGED HIS HE IDEA ABOUT HOW THE REACTION MIGHT
11 WORK CONSIDERABLY AND ABOUT A MONTH LATER IN OCTOBER 1983 HE
12 TRIED AGAIN, AND AGAIN HE FAILED. THERE WAS NO INDICATION IN
13 THAT REACTION EITHER HE WAS GETTING ANY AMPLIFICATION
14 WHATSOEVER.

15 NOW, BETWEEN THIS TIME AND THE NEXT EXPERIMENT DR.
16 MULLIS DID TWO THINGS: FIRST, HE THOUGHT MORE HOW HE MIGHT DO
17 PCR, BUT HE ALSO THOUGHT ABOUT THE PROBLEM OF DETECTING WHAT WAS
18 LIKELY TO BE IN THE FIRST INSTANCE A VERY WEAK REACTION. AND
19 THE SCHEME HE HIT UPON WAS ONE THAT WAS CAUSED PROOF THE
20 REACTION WAS WORKING, A LINE OR A BAND TO FORM ON AN X RAY FILM
21 IN A PARTICULAR SPOT.

22 SO IN DECEMBER 1983 HE SET UP TO DO THE EXPERIMENT
23 AGAIN. WE'RE NOW ABOUT A WEEK BEFORE CHRISTMAS IN 1983. HE DID
24 THE EXPERIMENT THE THIRD TIME. THIS IS THE TIME THAT THE DU
25 PONT WITNESSES SOMETIMES CALL THE FIRST SUCCESSFUL USE OF PCR BY

3
1 MR. MULLIS. HE HIMSELF WAS ACTUALLY RATHER MORE MODEST ABOUT IT
2 AND YOU'LL BOTH HEAR HIS TESTIMONY AND HAVE A CHANCE TO SEE WHAT
3 HE WROTE IN HIS LABORATORY NOTEBOOK.

4 YOU'LL RECALL THE TEST OF WHETHER OR NOT IT WORKED WAS
5 GOING TO BE THE BAND ON THIS FILM AND WHAT DR. MULLIS GOT IS A
6 VERY FAINT BAND PERHAPS, AND SO HE PUT THE PIECE OF FILM OR
7 PRINT OF IT IN HIS LABORATORY NOTEBOOK AND HE PUT THIS NOTE NEXT
8 TO IT.

9 AND THE NOTE YOU SEE SAYS: THERE WAS AN ARROW THERE,
10 HE WROTE ARROW MARKS THE SPOT WHERE TRUE BELIEVERS SEE A BAND.
11 THAT IS VERY FAINT AND MAYBE WITH A LITTLE BIT OF SQUINTING AND
12 IMAGINATION YOU SEE THE BAND.

13 WELL, DR. MULLIS KNEW THAT WASN'T GOING SO WORK TO SHOW
14 OTHER SCIENTISTS THAT PCR WORKED, SO HE KEPT WORKING AT THE
15 PROCESS. HE WORKED TO MAKE IT MORE ROBUST TO GET STRONGER
16 INDICATIONS AND HE WORKED ON OTHER METHODS OF DETECTING WHETHER
17 THE PROCESS WORKED. THESE EFFORTS OCCUPIED HIM THROUGH THE
18 SUMMER OF 1985. I'M SORRY, THROUGH THE SUMMER OF 1984.

19 DURING THAT TIME DR. MULLIS KEPT TELLING OTHERS IN THE
20 COMPANY ABOUT THE PROCESS HE WAS WORKING ON. HE SHOWED THEM THE
21 EVIDENCE HE WAS GETTING AND HE KEPT HEARING, WELL, MAYBE, OR IT
22 WILL NEVER WORK, OR THINGS OTHER THAN, YES, I SEE, I AGREE.

23 NOW, IN THE SUMMER OF 1984 YOU'LL HEAR THERE WAS A
24 MEETING OF ALL THE SCIENTISTS AT CETUS WHERE THEY GOT TOGETHER
25 AND SHOWED EACH OTHER THEIR WORK AND DR. MULLIS SHARED THE

3
1 RESULTS HE HAD AT THAT TIME. AND YOU'LL HEAR THAT AFTER THAT
2 MEETING THE CETUS MANAGEMENT MADE THE DECISION ABOUT PCR WHICH
3 PROVED TO BE VERY IMPORTANT.

4 THEY DECIDED THEY HAD TO KNOW WHETHER OR NOT IT WORKED,
5 AND THAT OTHER SCIENTISTS WERE GOING TO HAVE TO BE PUSHED TO
6 EVALUATE IT. SO WHAT THEY DECIDED WAS THAT DR. MULLIS SHOULD
7 START DIRECTLY WORKING WITH DOCTOR HENRY ERLICH'S LAB ON THIS
8 EFFORT TO COME UP WITH A SIMPLE, PRACTICAL METHOD OF DETECTING
9 GENETIC DISEASES. SO THE TWO LABORATORY DID START WORKING
10 TOGETHER.

11 IN NOVEMBER THEY CAME UP WITH A JOINT EXPERIMENT WHICH
12 WAS PROBABLY THE FIRST EXPERIMENT THAT CAUSED THE SIGNIFICANT
13 NUMBER OF OTHER SCIENTISTS, NON-TRUE-BELIEVERS IF YOU WILL, TO
14 START BELIEVING THAT PCR COULD BE MADE TO WORK.

15 WHAT HAPPENED IN THAT EXPERIMENT WAS DR. MULLIS'
16 LABORATORY TOOK SOME DNA FROM A PERSON WHO WAS INFLICTED WITH
17 SICKLE CELL ANEMIA. IT WAS AN EXPERIMENTAL BATCH OF DNA AND DR.
18 MULLIS' LABORATORY DID PCR ON THAT TO TRY AND AMPLIFY THE PART
19 OF THE DNA FROM THIS PERSON WHICH WOULD HAVE THE SICKLE CELL
20 GENE. THEY THEN GAVE THAT AMPLIFIED PRODUCT TO THE SCIENTISTS
21 AND DOCTOR ERLICH'S LABORATORY.

22 THE SCIENTISTS IN DOCTOR ERLICH'S LABORATORY SUBJECTED
23 THAT AMPLIFIED DNA TO THE TEST THEY HAD DEVELOPED FOR TRYING TO
24 FIND OUT WHETHER OR NOT SOME DNA HAD THE SICKLE CELL GENE IN IT.
25 THEY FOUND THAT THERE WAS A VERY STRONG DRAMATIC SIGNAL. FAR

4
1 STRONGER THAN ANYTHING THEY HAD EVER SEEN BEFORE.

2 THE SCIENTISTS WHO DID THE WORK WENT AROUND AND SHOWED
3 OTHERS THIS AND SUDDENLY THEY BEGAN TO BELIEVE THAT THE SECRET
4 COMING UP WITH THE TEST FOR SICKLE CELL AND OTHER BETWEEN ETHIC
5 DISEASES THAT THEY WERE SEARCHING FOR WOULD INVOLVING MARRYING
6 THE PCR PROCESS TO THEIR OWN DETECTION SYSTEM WHICH WAS CALLED
7 OLIGOMER RESTRICTION.

8 THE TWO LABORATORIES CONTINUED TO WORK ON THIS THROUGH
9 THE END OF THAT YEAR AND INTO 1985 AND BY THE SPRING THEY CAME
10 UP WITH A METHOD THEY FELT WAS REPRODUCIBLE, RELIABLE, ONE THEY
11 WERE PREPARED TO TELL THE OTHER SCIENTIFIC COMMUNITY ABOUT.
12 THAT'S JUST WHAT THEY DID.

13 THEY WROTE AN ARTICLE AND THEY PUT THEIR EXPERIMENTAL
14 RESULTS IN IT, THE DETAILS OF HOW THEY DID THE PCR AND THE OR,
15 AND THEY SUBMITTED THAT MANUSCRIPT TO A PRESTIGIOUS SCIENTIFIC
16 MAGAZINE MAYBE THE MOST PRESTIGIOUS IN THIS COUNTRY, SCIENCE.
17 IT WAS ACCEPTED BY SCIENCE AS THE PRINCIPAL ARTICLE FOR DECEMBER
18 1985 ISSUE AND THAT'S WHERE IT PUBLISHED.

19 IN THAT ARTICLE THE PRINCIPAL FOCUS WAS ON USING A
20 METHOD OF DETECTING SICKLE CELL ANEMIA AND SHOWING THEY NOW HAD
21 A METHOD THAT WOULD DO THAT. A GOAL THAT SEVERAL SCIENTISTS
22 WERE WORKING FOR AT THE TIME.

23 IN FACT, YOU'LL HEAR DURING THIS TRIAL FROM ANOTHER OF
24 THOSE SCIENTISTS, ONE OF DU PONT'S WITNESSES DOCTOR BRUCE
25 WALLACE, HAD ALSO SPENT MANY YEARS TRYING TO COME UP WITH A

4
1 PRACTICAL METHOD OF DETECTING SICKLE CELL ANEMIA. AND YOU'LL
2 HEAR DR. WALLACE IN HIS WRITINGS AFTER HE LEARNED OF THE CETUS
3 METHOD WAS VERY CONGRATULATORY OF THEM FOR HAVING INVENTED PCR
4 AS A METHOD WHICH WOULD ACCOMPLISH THIS.

5 BUT TO GET BACK TO SCIENCE MAGAZINE. IN THIS SCIENCE
6 MAGAZINE IN 1985 THE CETUS SCIENTISTS LAID OUT THE DETAILS OF
7 HOW TO DO PCR. THERE WAS A VERY DETAILED DISCLOSURE, A RECIPE,
8 IF YOU WILL, THAT SCIENTISTS IN ANY LABORATORY COULD FOLLOW AND
9 DO PCR.

10 THIS RECIPE WAS PUT INTO ONE OF THE CAPTIONS TO ONE OF
11 THE EXPERIMENTAL RESULTS WHICH IS WHAT THEY DID AND IT TOLD
12 OTHER SCIENTISTS EXACTLY HOW MUCH PRECISELY EACH INGREDIENT TO
13 PUT IN. IT TOLD THEM EXACTLY HOW LONG AND AT WHAT TEMPERATURE
14 TO DO THE VARIOUS STEPS AND IT WAS MUCH LIKE A VERY COMPLICATED
15 CAKE BAKING RECIPE, IF YOU WILL. AS LONG AS YOU FOLLOWED EVERY
16 STEP, YOU DID EXACTLY WHAT WAS THERE, YOU WOULD SUCCESSFULLY
17 ACCOMPLISH PCR.

18 NOW, YOU WILL HEAR FROM DU PONT ABOUT A MEMORANDUM THAT
19 DOCTOR ERLICH WROTE TO HIS COLLEAGUES AT CETUS. IN FACT, THAT'S
20 ONE YOU'VE ALREADY SEEN HERE THIS MORNING. AND DU PONT WILL
21 SUGGEST THERE WAS SOME DISPUTE ABOUT PUBLISHING THIS ARTICLE,
22 THAT'S WHAT THE MEMORANDUM IS ABOUT. YOU'LL SEE THE MEMORANDUM
23 YOURSELF AND YOU'LL SEE THE MEMORANDUM HAD NOTHING TO DO WITH
24 THAT AT ALL. YOU'LL SEE THAT MEMORANDUM FROM DOCTOR ERLICH
25 ESSENTIALLY SAYS THIS:

4 1 THIS ARTICLE, THE ONE WITH THIS DETAILED RECIPE HAD
2 ALREADY BEEN SENT TO SCIENCE MAGAZINE. IT WAS ALREADY SENT AND
3 GOING TO BE PUBLISHED. THEY'VE ALREADY BEEN TOLD BY SCIENCE
4 THIS DETAILED RECIPE WAS GOING TO BE PUBLISHED.

5 NOW, THERE WAS A SECOND MANUSCRIPT, ONE THAT DR. MULLIS
6 AND HIS LABORATORY ASSISTANT, MR. FRED FALOONA, HAD PREPARED.
7 THE CONTROVERSY WAS NOT ABOUT PUBLISHING THIS DETAILED RECIPE,
8 BUT WHETHER OR NOT MR. FALOONA AND MR. MULLIS COULD PUBLISH
9 THEIR ARTICLE.

10 AND YOU'LL HEAR WHAT MR. ERLICH WAS TELLING HIS
11 COLLEAGUES, HE'LL EXPLAIN THIS HIMSELF. HE WAS TELLING HIS
12 COLLEAGUES WHAT'S IN THIS CAPTION WE'VE ALREADY TOLD SOMEONE HOW
13 TO DO IT. WE LAID IT OUT IN EXCRUCIATING DETAIL. THERE'S NO
14 REASON NOT TO PUBLISH THE MULLIS' PIECE. SURE IT TELLS PEOPLE
15 OTHER THINGS THEY CAN DO WITH IT, BUT ANY GOOD MOLECULAR
16 BIOLOGIST WOULD BE ABLE TO FIGURE THOSE OTHER THINGS OUT NOW
17 THAT WE'VE TOLD PEOPLE HOW TO DO IT.

18 YOU WON'T SEE ANY ADMISSION BY DOCTOR ERLICH THAT SOME
19 VAGUE NOTION OF HOW TO DO THIS WOULD HAVE ENABLED HIM. HE WILL
20 TESTIFY IT'S HIS VIEW YOU HAVE TO GIVE THE DETAILS AND THE
21 MANNER THAT YOU SAW IN THAT CAPTION TO ENABLE OTHER PEOPLE TO DO
22 IT.

23 NOW, AMONG THE PEOPLE WHO SAW THIS DECEMBER 1985
24 PUBLICATION IN SCIENCE MAGAZINE WAS ONE OF THE DEANS OF THE
25 BIOTECHNOLOGY MOVEMENT, DOCTOR JAMES WATSON WHO RUNS A VERY

5 1 FAMOUS LABORATORY IN COLD SPRING HARBOR, NEW YORK.

2 DOCTOR JAMES WATSON TOOK NOTE OF THE ARTICLE AND
3 RECOGNIZED IN IT THE POWER OF PCR, EVEN THOUGH THE ARTICLE
4 ITSELF DIDN'T SPELL IT OUT. DOCTOR WATSON BECAUSE OF THE
5 ARTICLE INVITED DOCTOR KARY MULLIS TO COME AND SPEAK AT A
6 PRESTIGIOUS GATHERING OF THE ELITE OF THE PROFESSION, IF YOU
7 WILL, THAT TAKES PLACE ANNUALLY. THIS ONE WAS IN JUNE 1986.

8 SO IN JUNE 1986 DR. MULLIS TRAVELED TO COLD SPRING
9 HARBOR, NEW YORK AND ALONG WITH HIS PIECE HE PRESENTED HIS
10 PAPER, A PAPER ON PCR AND A PAPER THAT WENT FAR BEYOND THE
11 SICKLE CELL NOTION.

12 IN THAT PAPER YOU'LL SEE DR. MULLIS SPELLED OUT A LOT
13 OF THE OTHER THINGS HE HAD DONE AND A LOT OF THE IDEAS HE HAD
14 BEYOND USING THE CYCLE CELL TEST. THAT IS, THAT PCR WAS A
15 POWERFUL TOOL WITH A LOT OF USES.

16 YOU'LL HEAR THAT THE AUDIENCE AT THAT MEETING WAS VERY
17 IMPRESSED BY DR. MULLIS' DISCLOSURE. AFTER HE SPOKE HE FOUND
18 HIMSELF SURROUNDED BY A GROUP OF SCIENTISTS WHO WANTED MORE
19 DETAILS THEN AND THERE SO THEY COULD START USING PCR TO HELP
20 THEM IN THEIR WORK.

21 NOW, THIS JUNE 1986 MEETING WAS THE FIRST OF MANY TIMES
22 THAT DR. MULLIS AND, IN FACT, MANY OF THE CETUS SCIENTISTS FOUND
23 THEMSELVES SPEAKING ABOUT PCR AND BEING CONGRADULATED BY THEIR
24 PEERS. SINCE THAT TIME SEVERAL OF THEM HAVE BEEN HONORED BY
25 THEIR PEERS IN VARIOUS ORGANIZATIONS AND YOU'LL HEAR ABOUT THAT,

5
1 BUT THE SERIES OF HONORS WAS PROBABLY BEST CAPPED OFF BY SCIENCE
2 MAGAZINE IN LATE 1989. SCIENCE MAGAZINE DECIDED IT WOULD START
3 NAMING A DEVELOPMENT OF THE YEAR. THE DEVELOPMENT THAT PEOPLE
4 AT SCIENCE MAGAZINE THOUGHT WAS MOST LIKELY TO HAVE AN IMPACT ON
5 HISTORY.

6 FOR THE FIRST OF THESE AWARDS THE EDITORS OF SCIENCE
7 CHOSE THE POLYMERASE CHAIN REACTION. SO THE DECEMBER 1989 ISSUE
8 OF SCIENCE HAD THIS COVER AND THEN INSIDE THEY PUBLISHED AN
9 ARTICLE ABOUT THE MOLECULE OF THE YEAR EXPLAINING THAT THIS
10 YEAR'S AWARD GOES TO THE DNA POLYMERASE MOLECULE AND TECHNIQUE
11 CALLED POLYMERASE CHAIN REACTION.

12 PCR AS IT'S CALLED THEY SAID HAS DEVELOPED INTO ONE OF
13 THE MOST POWERFULL TOOLS OF MODERN BIOLOGY. THEY SAID ITS
14 REVOLUTIONIZING THE APPROACHES RESEARCHERS ARE TAKING TO MANY
15 PROBLEMS IN BIOLOGY. THEN THEY WENT ON IN A SEPARATE ARTICLE
16 ABOUT PCR TO POINT OUT OTHER OF ITS ATTRIBUTES.

17 LET ME SWITCH SIDES HERE. THEY POINTED OUT THE PCR
18 PAPERS WERE FIRST PUBLISHED IN 1985, IN FACT, IN AN EARLIER
19 ISSUE OF SCIENCE AND THAT SINCE THAT TIME PCR HAD GROWN INTO AN
20 INCREASINGLY POWERFUL AND VERSATILE AND USEFUL TECHNIQUE.

21 THEY EXPLAINED WHAT PCR DID WAS TAKE TINY BITS OF
22 EMBEDDED, OFTEN HIDDEN GENETIC INFORMATION AND AMPLIFIED IT INTO
23 LARGE QUANTITIES OF ACCESSIBLE, IDENTIFIABLE AND ANALYZABLE
24 MATERIAL. SO WITH THIS AWARD PCR ESSENTIALLY WAS HONORED BY THE
25 PROFESSION AS THE MOST IMPORTANT OF THE DEVELOPMENTS THAT WAS

6
1 AROUND AT THE TIME.

2 NOW, WITH THIS KIND OF A CLAIM THERE REALLY SHOULDN'T
3 BE ANY QUESTION ABOUT THE IMPORTANCE OF PCR AND THAT IT WAS A
4 REVOLUTIONARY TECHNIQUE, WHICH WOULD HAVE BEEN IMPORTANT AT ANY
5 TIME. IT WOULD HAVE BEEN IMPORTANT IN 1972, IN 1980, IN 1990.
6 IN FACT, THE DU PONT SCIENTISTS HAD BEEN AS QUICK AS ANYONE TO
7 TALK ABOUT THE REVOLUTIONARY NATURE OF PCR.

8 IN 1989 ONE OF THE DU PONT MANAGER SCIENTISTS WROTE
9 THIS MEMORANDUM TO HIS BOSS. AS YOU CAN SEE HE, TOO, THOUGHT
10 THAT PCR HAD ALREADY REVOLUTIONIZED THE THINKING OF
11 BIOTECHNOLOGY RESEARCH COMMUNITY AND HE ADDED THAT PROMISES TO
12 HAVE A MAJOR IMPACT IN DIAGNOSTICS. THAT IS, THE USE OF A PCR
13 FOR DIAGNOSING GENTIC AND OTHER DISEASES.

14 OTHER SCIENTISTS AT DU PONT ADD TO THAT. A GROUP HAD
15 BEEN FORMED AT DU PONT TO TRY TO DECIDE WHETHER OR NOT DU PONT
16 WANTED TO LICENSE PCR. WHETHER IT WAS WORTH THE EFFORT IN THE
17 LIKELY COST. THAT GROUP HAD A MEETING WHERE THEY PREPARED A
18 SERIES OF SLIDES.

19 DURING THE TRIAL WE'LL SHOW YOU SEVERAL OF THEM. THIS
20 WAS ESSENTIALLY THEIR SUMMARY. IT BEGAN THE OPPORTUNITY POINTED
21 OUT CETUS CORPORATION HAD DEVELOPED A PROPRIETARY METHOD FOR
22 AMPLIFICATION OF A NUCLEIC ACID TARGET. IT THEN GOES ON AND
23 TALKS ABOUT WHAT IT IS PCR CAN DO IN MUCH THE SAME LANGUAGE OF
24 THE OTHER LAUDATORY REMARKS THAT HAD BEEN WRITTEN.

25 IT ALSO CONCLUDED CRITICAL PATENT REVIEW CONFIRM

6

1 UNIQUENESS OF THE TECHNOLOGY, THAT IS OF THE PCR TECHNOLOGY.
2 THIS WAS WHAT THE DU PONT SCIENTISTS WERE WRITING BEFORE DU PONT
3 DECIDED TO BRING THIS SUIT.

4 NOW, THIS REAL WORLD EVIDENT THE STATEMENT OF
5 SCIENTISTS OUTSIDE THIS COURTROOM, STATEMENTS THEY MADE TO THEIR
6 COLLEAGUES AS THEY WERE TRYING TO DO REAL SCIENTIFIC WORK AN
7 IMPORTANT PART OF THE EVIDENCE THAT WE WILL PRESENT TO YOU. YOU
8 WILL SEE THAT THIS REAL WORLD EVIDENCE THROUGH THE TIME THAT DU
9 PONT DECIDED TO BRING THIS SUIT WAS UNIVERSAL IN APPLAUDING PCR
10 AND APPLAUDING THE CETUS SCIENTISTS WHO BROUGHT IT TO THE
11 SCIENTIFIC COMMUNITY.

12 NOW, AFTER DU PONT DECIDED TO BRING THIS SUIT SOME
13 SCIENTISTS HAVE SAID OTHER THINGS. LET ME GIVE YOU AN EXAMPLE.
14 ONE SCIENTISTS YOU'LL HEAR FROM A DU PONT WITNESS DOCTOR IAN
15 MOLINEUX. DOCTOR MOLINEUX WORKED IN THE LABORATORY OF DOCTOR
16 KHORANA AND NOW A PROFESSOR DOWN IN TEXAS.

17 YOU'LL HEAR FROM DOCTOR MOLINEUX KNEW HE WAS WELL AWARE
18 PCR FROM THE VARIOUS CETUS REPORTS AND ALL THE OTHER ATTENTION
19 THE REACTION WAS GETTING. HE CERTAINLY KNEW IT WAS THERE AND HE
20 KNEW IT WAS QUITE IMPORTANT. IN FACT, YOU'LL HEAR HE WAS
21 TEACHING IT TO HIS STUDENTS THERE AT THE UNIVERSITY.

22 AND YOU WILL HEAR THAT, ALTHOUGH DOCTOR MOLINEUX WAS
23 FULLY AWARE OF PCR, HE DIDN'T THINK IT RELATED TO ANYTHING THAT
24 HE HAD DONE IN DOCTOR KHORANA'S LABORATORY. OR AT LEAST HE
25 DIDN'T THINK THAT UNTIL HE WAS VISITED BY ONE OF THE DU PONT

6
1 SCIENTISTS AND -- I'M SORRY, ONE OF THE DU PONT LAWYERS, AND THE
2 TWO OF THEM HAD A CONVERSATION AND THEN MR. MOLINEUX TELLS US HE
3 REALIZED THAT, YES, IN MR. KHORANA'S LABORATORY HE HAD DONE PCR.

4 THE SAME IS TRUE OF OTHER SCIENTISTS, BOTH THOSE IN AND
5 OUT OF DOCTOR KHORANA'S LABORATORY. SINCE DU PONT'S FILED ITS
6 SUIT IT HAS BEEN SUCCESSFUL IN GETTING A SMATTERING OF
7 SCIENTISTS TO SIGN ON TO THE NOTION THAT PCR IS THE SAME AS WHAT
8 WAS GOING ON IN DOCTOR KHORANA'S LABORATORY.

7
9 LET ME GIVE YOU ONE MORE EXAMPLE OF THAT. ONE OF THE
10 SCIENTISTS WHOSE DECLARATIONS THAT DU PONT PRESENTED TO THE
11 PATENT OFFICE WAS A SCIENTIST NAMED SAMBROOK, AND DOCTOR
12 SAMBROOK WAS ONE OF A GROUP OF THREE SCIENTISTS WHO FROM TIME TO
13 TIME WROTE A LARGE MANUAL OF ALL THE USEFUL TECHNIQUES THAT
14 BIOTECHNOLOGY MIGHT -- PEOPLE WORKING IN BIOTECHNOLOGY MIGHT
15 NEED. AND THESE CHARGED COMPENDIUMS OF TECHNIQUES WERE
16 PUBLISHED IN 1982, THEN MUCH EXPANDED VERSION IN 1989.

17 NOW, IN 1982 PCR WASN'T IN THE MANUAL. IN 1989 THERE'S
18 A WHOLE CHAPTER IN THE MANUAL ABOUT IT. DOCTOR SAMBROOK AND HIS
19 CO-AUTHORS WROTE A PREFACE IN WHICH THEY POINTED OUT THAT NEW
20 SECTIONS HAD BEEN ADDED TO THE 1989 MANUAL TO DEAL WITH RECENTLY
21 INVENTED TECHNIQUES, SUCH AS AMPLIFICATION OF DNA BY THE
22 POLYMERSE CHAIN REACTION.

23 NOW, SOMETIME AFTER DOCTOR SAMBROOK WROTE THAT YOU'LL
24 SEE HE BEGAN TO SERVE AS AN EXPERT FOR DU PONT AND HE THEN TOLD
25 THE PATENT OFFICE THE NEXT YEAR IN 1990 THAT, IN FACT, PCR

7
1 WASN'T RECENTLY INVENTED AS HE SAID THERE IN THE PREFACE. HE'LL
2 SAY PCR WAS OLD, IT WAS IN THE ARTICLES FROM THE 1970'S FROM THE
3 KHORANA LABORATORY. SO THAT'S THE KIND OF CHANGED VIEW OF
4 SCIENTISTS THAT HAPPENED AFTER DU PONT DECIDED TO FILE THIS SUIT
5 AND YOU'LL SEE SEVERAL EXAMPLES OF THAT.

6 NOW, DURING THE TIME OTHER REAL WORLD EVIDENCE YOU'LL
7 HEAR WILL BE REAL WORLD EVIDENCE ABOUT THE RELATIONSHIP OF
8 EVENTS AND THE TIME PERIODS THAT HAPPEN BETWEEN THEM. LET ME BE
9 SPECIFIC. DOCTOR KHORANA DID HIS WORK BACK IN THE EARLY 1970'S,
10 AND WE'VE GOT VARIOUS INDICATIONS HERE. THIS IS THE DATE WHEN
11 DOCTOR KJELL KLEPPE HAD SOME NOTEBOOK ENTRIES THAT DU PONT IS
12 GOING TO PRESENT AS BEING EVIDENCE OF PCR.

13 THIS IS THE DATE OF PUBLICATION OF THE FIRST OF THE
14 ARTICLES, THE ARTICLE THAT'S CALLED KLEPPE ET AL., IT'S IN 1971.
15 THESE VARIOUS KHORANA ENTRIES CONTINUE THROUGH 1973 OR 1975,
16 THEN THEY END.

17 NOW, EVEN IF ONE ASSUMES THAT IN 1975 SOMETHING WAS
18 MISSING TO MAKE PCR CONVENIENT OR EASY, TIME PASSES AND WE GET
19 TO THE END OF THE 1970'S AND IN THE END OF THE 1970'S, CERTAINLY
20 BY THE BEGINNING OF THE 1980'S EVERYTHING NECESSARY TO DO PCR
21 WAS AVAILABLE TO ANYONE WHO WANTED IT, AND YET STILL NOBODY IS
22 DOING PCR.

23 WE COME TO 1983 AND THAT IS, AS I TOLD YOU EARLIER, WAS
24 WHEN MR. MULLIS HAD HIS INSPIRATION AND DID THE FIRST PCR
25 EXPERIMENTS. STILL NOBODY IS DOING PCR EXCEPT THE SCIENTISTS AT

7
1 CETUS. BETWEEN 1983 AND 1985 THE SCIENTISTS AT CETUS MADE PCR
2 INTO A SIMPLE EASY TECHNIQUE. THEY DEVELOPED A RECIPE FOR DOING
3 IT. STILL NOBODY ELSE WAS DOING PCR EXCEPT THE SCIENTISTS AT
4 CETUS.

5 IN DECEMBER 1985 THE ARTICLE WAS PUBLISHED IN SCIENCE.
6 SUDDENLY YOU'LL SEE THERE'S AN EXPLOSION OF USE OF PCR. THERE'S
7 THE KIND OF LAUDATORY COMMENTS WE'VE SEEN. PCR STARTING WITH
8 THIS PUBLICATION IN 1975, QUICKLY IS THE ARTICLES PUT IT
9 REVOLUTIONIZES BIOLOGY. IT REVOLUTIONIZES THE APPROACH THAT
10 PEOPLE WORKING IN THIS FIELD CAN TAKE BECAUSE IT'S SUCH A SIMPLE
11 POWERFUL TECHNIQUE. YET, THROUGHOUT ALL THIS TIME WHEN YOU'RE
12 GOING TO HEAR FROM WITNESSES PCR WAS KNOWN, NOBODY IS DOING IT.

13 NOW, IT CERTAINLY ISN'T TRUE THAT THERE WAS NOBODY
14 DURING THAT TIME WHO COULD HAVE BENEFITED FROM PCR. YOU'LL HEAR
15 FROM SOME SCIENTISTS WHO WILL TELL YOU HOW DESPERATELY THEY
16 COULD HAVE USED THE TECHNIQUE, WHAT PCR DOES.

17 AGAIN, I'M JUST GOING TO CHOSE ONE EXAMPLE. DOCTOR
18 FRENCH ANDERSON IS THE HEAD OF A LABORATORY AT THE NATIONAL
19 INSTITUTES OF HEALTH IN WASHINGTON D.C. IT'S A GOVERNMENT
20 LABORATORY. DOCTOR ANDERSON IS A RARE INDIVIDUAL EVEN AMONG THE
21 WORLD CLASS SCIENTISTS YOU'LL SEE IN THIS COURTROOM.

22 HE FOR YEARS AND YEARS AND YEARS, LONG BEFORE EVEN
23 CONCEIVABLY WAS POSSIBLE HAS STRUGGLED TO BRING TOGETHER THE
24 BITS AND PIECES OF BIOTECHNOLOGY WHICH MIGHT BE USED TO TREAT
25 GENETIC DISEASES. NOT JUST TO DETECT THEM LIKE THE CETUS

8
1 SCIENTISTS AND OTHERS WERE DOING, BUT TO ACTUALLY DO TREATMENT,
2 GENE THERAPY TREATMENT.

3 YOU'LL HEAR FROM DOCTOR ANDERSON IT NOW APPEARS HE'S
4 HOPEFULLY ON THE VERGE OF SUCCESSES, RECEIVED CONSENT FROM THE
5 FOOD AND DRUG ADMINISTRATION TO ADMINISTER THE FIRST OF THESE
6 THERAPIST TO A YOUNG GIRL WHO'S SUFFERING FROM SKIDS, THE IMMUNE
7 SYSTEM DISEASE THAT MAKES CHILDREN SUBJECT TO INFECTION AND
8 DEATH.

9 NOW, DOCTOR ANDERSON WILL TELL YOU THAT AS HE STRUGGLED
10 TO PUT TOGETHER THE BITS AND PIECES NECESSARY TO DO GENE
11 THERAPY, ONE OF THE BIG HOLES WAS HAVING A DETECTION METHOD HE
12 COULD USE SO HE COULD TELL WHETHER OR NOT THE THERAPY WAS
13 WORKING. HE NEEDED SOMETHING SO HE COULD TAKE A SAMPLE FROM THE
14 PATIENT AND AMPLIFY IT UP TO HUGE QUANTITIES WITH THE RESULT
15 THAT HE COULD DETECT THAT HE WAS ACTUALLY GETTING SOME RESULTS.
16 HE'LL TELL YOU THE ABSENCE OF SUCH AN AMPLIFICATION TECHNIQUE
17 WAS A BIG PROBLEM.

18 NOW, DOCTOR ANDERSON CERTAINLY KNEW ALL ABOUT THE KIND
19 OF PRIMER EXTENSION REACTION, THE REPLICATION REACTIONS THAT
20 WERE GOING ON IN THE EARLY 1970'S. IN FACT, HE PUBLISHED SOME
21 REPLICATION REACTION WORK HIMSELF. HE USED PRIMER EXTENSIONS IN
22 HIS WORK REPEATLY. HE ENOUGH HOW TO DO THEM. HIS PEOPLE IN HIS
23 LABORATORY DID THEM ROUTINELY.

24 YET, DOCTOR ANDERSON WILL TELL YOU HE DIDN'T THINK FROM
25 THAT WORK THAT DOING SOMETHING LIKE PCR WAS POSSIBLE. AND, IN

8
1 FACT, HE'LL TELL YOU HE WAS ABSOLUTELY CONVINCED IT WAS
2 IMPOSSIBLE AND HE'LL GIVE YOU SOME OF THE REASONS WHY.

3 HE'LL TELL YOU HE WAS SO CONVINCED IT WAS IMPOSSIBLE,
4 EVEN AFTER HE READ THE ARTICLE THAT THE CETUS SCIENTISTS
5 PUBLISHED HE THOUGHT THEY MADE A MISTAKE. HE THOUGHT THERE WAS
6 SOMETHING WRONG WITH THEIR DETECTION SYSTEM AND WIND UP BEING
7 EMBARRASSED FOR PUBLISHING WHAT HE THOUGHT TO BE A RIDICULOUS
8 CLAIM.

9 IN TIME DOCTOR ANDERSON WAS CONVINCED. ONE OF THE
10 PEOPLE WHO WORKED IN HIS OWN LABORATORY AND DID PCR AND REPORTED
11 BACK TO HIM IT REALLY WORK. NOW, DOCTOR ANDERSON LIKE THOUSANDS
12 OF OTHER SCIENTISTS USES PCR IN HIS LABORATORY IN ORDER TO
13 ACCOMPLISH HIS WORK.

14 LET ME TALK FOR A MINUTE ABOUT SPECIFICALLY WHY PCR
15 IS SO IMPORTANT. NOW, AS WE'VE TALKED ABOUT THE IDEA OF HAVING
16 A PRIMER EXTENSION REACTION WAS WELL-KNOWN FROM THE EARLY
17 1970'S, THAT'S THE KIND OF WORK DOCTOR KHORANA PUBLISHED. IT
18 WAS KNOWN THAT YOU COULD USE A PRIMER EXTENSION REACTION TO COPY
19 A STRAND OF DNA.

20 BUT THERE'S AN IMPORTANT DIFFERENCE. THE PRIMER
21 EXTENSION REACTION, THE REPAIR REPLICATIONS REACTIONS THEY WERE
22 CALLED BACK THEN, COPIED STRANDS ONE AT A TIME. SO YOU MAKE
23 COPY AND THEN YOU GO BACK YOUR ORIGINAL TEMPLATE, FROM THE
24 ORIGINAL TEMPLATE YOU MAKE ANOTHER COPY. THEN YOU DO ANOTHER
25 CYCLE WITH THE ORIGINAL TEMPLATE AND MAKE ANOTHER COPY.

8
1 SO AFTER ONE CYCLE YOU GET TWO COPIES. AFTER TWO
2 CYCLES YOU HAVE THREE COPIES, THE ORIGINAL PLUS THE TWO YOU
3 MADE. PCR IS DRAMATICALLY DIFFERENT AND PARTICULARLY ONCE YOU
4 GET INTO THE NUMBERS LIKE FIVE OR TEN, WE HAVE A CHART WHICH
5 SHOWS THIS.

6 THE CHART ON YOUR LEFT SHOWS WHAT HAPPENS IN AN
7 AMPLIFICATION. YOU CAN SEE THAT -- MAYBE WE COULD SET THESE UP.
8 YOU CAN SEE THAT YOU HAVE ONE STRAND TO BEGIN WITH AND AFTER ONE
9 CYCLE YOU GOT THE ORIGINAL STRAND PLUS ONE. AFTER TWO CYCLES
10 YOU'VE GOT THE ORIGINAL STRAND PLUS TWO.

11 THEN MOVING DOWN AFTER TEN CYCLES YOU GOT THE ORIGINAL
12 STRAND PLUS TEN, AFTER 30 CYCLES YOU GOT THE ORIGINAL STRAND
13 PLUS 30 COPIES, SO GOING THROUGH 30 CYCLES IS GIVING YOU 31
14 COPIES. NOW, PCR IS QUITE DIFFERENT.

15 AND WHAT HAPPENS IN PCR IS THAT AT LEAST THE AMOUNT OF
16 STRANDS YOU MAKE DOUBLES IN EVERY CYCLE. SO IN THE FIRST ROUND
17 AGAIN YOU MAKE ONE AND HAVE TWO, BUT AFTER THE SECOND CYCLE
18 YOU'VE GOT FOUR, AFTER THE NEXT CYCLE YOU'VE GOT EIGHT, AND ALL
19 THAT ONCE YOU GET TO TEN CYCLES BECAUSE THEN INSTEAD OF HAVING
20 11 STRANDS YOU GOT 1,000 AND AFTER 20 CYCLES INSTEAD OF HAVING
21 21 STRANDS YOU HAVE APPROXIMATELY A MILLION AND AFTER 30 CYCLES
22 WHICH IS ABOUT THE PRACTICAL LIMIT OF PCR, INSTEAD OF 31 STRANDS
23 YOU HAVE SOMETHING LIKE A BILLION COPIES. THAT IS ENORMOUSLY
24 POWERFUL AMPLIFICATION TECHNIQUE.

25 NOW, THIS IS WHAT THE CETUS PATENT, WHAT MAKES THE

9
1 AMPLIFICATION EXPONENTIAL IN PCR, IS THAT IN EACH CYCLE OF PCR
2 THE PRODUCT THAT YOU MADE FROM THE PRIOR CYCLE IS USED AS
3 TEMPLATE IN THE NEXT CYCLE. SO IN THE FIRST CYCLE YOU USE YOUR
4 ORIGINAL DNA AND MAKE ONE COPY.

5 IN THE NEXT CYCLE BOTH OF THOSE STRANDS, THE ORIGINAL
6 ONE AND THE COPY ARE BOTH COPIED AND SO AFTER THEY'RE EACH
7 COPIED YOU GOT FOUR. IN THE NEXT CYCLE EACH OF THOSE FOUR IS
8 COPIED AND YOU GET EIGHT, AND YOU GET TO NUMBERS LIKE 1,000, A
9 MILLION, A BILLION, BECAUSE THAT'S THE POWER OF MULTIPLYING TWO
10 BY ITSELF TEN TIMES, 20 TIMES, 30 TIMES.

11 NOW, WHAT CETUS PATENTED WHEN IT PATENTED PCR WAS NOT
12 THE USE OF A PRIMER EXTENSION REACTION TO MAKE A COPY, BUT THE
13 USE OF A REACTION WHICH USES THE PRODUCT OF EACH CYCLE IN ORDER
14 TO BE TEMPLATE AND LATER CYCLES WITH THE RESULT THAT YOU GET
15 EXPONENTIAL AMPLIFICATION. AS YOU WILL SEE THE CLAIMS AND HAVE
16 THEM ANALYZED FOR YOU THIS WILL BECOME VERY CLEAR TO YOU.

17 LET US JUST SHOW YOU THE ONE PATENT, THE BASIC
18 AMPLIFICATION PATENT AS AN EXAMPLE. THIS IS A PATENT CLAIM
19 WHICH AS IT SAYS COVERS THE PROCESS FOR AMPLIFYING AND IT
20 AMPLIFIES AT LEAST ONE SPECIFIC NUCLEIC ACID SEQUENCE. THAT IS
21 YOU GOT A TARGET OUT THERE THAT YOU'RE TRYING TO AMPLIFY AND
22 THIS SPECIFICALLY COPIES WHAT IT IS YOU'RE TRYING TO COPY.

23 WELL, IT WILL BE AN IMPORTANT POINT LATER. IT MAKES
24 THAT COPY IN A WAY SUCH THAT THE PRODUCTS SYNTHESIZED IN ONE
25 CYCLE IS SEPARATED FROM ITS OTHER HALF AND THEN THAT PRODUCT CAN

9
1 SERVE AS A TEMPLATE IN LATER ROUNDS AND THE CLAIM GOES ON THEN
2 TO THE NEXT CYCLE AND SAYS IN THE LATER ROUND YOU, IN FACT, USE
3 THE PRODUCT THAT WAS SYNTHESIZED ABOVE IN ORDER TO PRODUCE
4 ANOTHER STRAND.

5 THAT IS THE CLAIMS SPECIFICALLY READ ON THIS
6 EXPONENTIAL COPYING TECHNIQUE, NOT LINEAR BUT ONLY EXPONENTIAL.
7 THE ONLY KIND OF COPYING THAT COMES WITHIN THE PCR PATENT A
8 COPYING EXPONENTIAL IT USES THE PRODUCT OF ONE STRAND AS
9 TEMPLATE IN LATER REACTIONS. IT'S A POINT YOU'LL HEAR US AND
10 OUR WITNESSES TALKING A LOT ABOUT.

11 NOW, AS LONG AS I'VE GOTTEN INTO THE PATENTS LET ME SAY
12 A FEW WORDS ABOUT THE PATENT PROCESS AND HOW WE GOTTEN TO WHERE
13 WE ARE. THE ORIGINAL PATENTS WERE ISSUED BY THE UNITED STATES
14 PATENT AND TRADEMARK OFFICE IN 1987 AND YOU'LL HEAR HOW THE
15 PROCESS INVOLVED ABOUT TWO YEARS.

16 THEY WERE FILED IN 1985 AND THEN THERE WAS VARIOUS
17 COMMUNICATIONS BACK AND FORTH BETWEEN THE CETUS LAWYERS AND
18 SCIENTISTS AND THE PATENT EXAMINER AND IN THE END THE PATENT
19 EXAMINER DECIDED THE CLAIMS THAT ARE IN THESE PATENTS ARE PROPER
20 UNDER THE LAW.

21 YOU'LL HEAR THE PATENT EXAMINER WHO MADE THAT DECISION
22 IS AN EXPERT. HE'S AN EXPERT BOTH IN PATENT LAW AND HE'S AN
23 EXPERT SCIENTIST, A MAN WHO HIMSELF HAS A PHD.

24 AND AFTER HIS CAREFUL REVIEW THIS EXPERT SCIENTISTS HIS
25 NAME IS DR. MARTINELL CONCLUDED THE CETUS CLAIMS PROPERLY WERE

9
1 PATENTABLE AND HE ISSUED THE PATENTS.

2 NOW, YOU'LL HEAR THAT THAT INITIAL APPLICATION WAS
3 FILED WITH REFERENCE TO PRIMER EXTENSION REACTIONS, BUT NOT
4 SPECIFICALLY TO DR. KHORANA'S WORK, AND THAT'S BECAUSE NO ONE
5 KNEW AT THE TIME DU PONT WAS GOING TO LATER MAKE THE CLAIM THAT
6 IT WAS THE KHORANA WORK WHICH INVALIDATED THE PATENTS.

10
7 WHAT COULD HAVE BEEN A VERY DIFFICULT ISSUE FOR US,
8 THOUGH, IS NOT. THAT'S BECAUSE THE PATENT OFFICE WAS
9 SPECIFICALLY ASKED, DOES THIS KHORANA WORK MAKE A DIFFERENCE AND
10 THEY SPECIFICALLY ANSWERED, NO, IT DOESN'T.

11 THAT CAME ABOUT UNDER A SPECIAL PROCEDURE THAT CONGRESS
12 CREATED CALLED THE RE-EXAMINATION PROCEEDING THERE WERE TWO OF
13 THEM HERE. THE FIRST WAS BROUGHT BY CETUS LICENSEE HOFFMAN-LA
14 ROCHE. WHAT HOFFMAN-LA ROCHE DID, THEY SAW THIS LAWSUIT HAD
15 BEEN FILED, IN THIS LAWSUIT DU PONT WAS MAKING CLAIMS THAT
16 CERTAIN PUBLICATIONS INVALIDATED THE PATENT.

17 HOFFMAN-LA ROCHE WANTED TO GET THE VIEWS OF THE EXPERT
18 EXAMINERS AT THE PATENT OFFICE ON THAT QUESTION. SO IN A VERY
19 UP FRONT WAY HOFFMAN-LA ROCHE WENT TO THE PATENT OFFICE AND SAID
20 WE ARE CETUS' LICENSEE, DU PONT HAS FILED A LAWSUIT IN WHICH IT
21 CLAIMS THESE WRITTEN PUBLICATIONS INVALIDATE THE PATENT. WE
22 WANT TO KNOW YOUR VIEWS. PLEASE RE-EXAMINE THE PATENT AND TELL
23 US WHETHER OR NOT IT IS VALID IN LIGHT OF THESE PUBLICATIONS
24 FROM THE KHORANA LABORATORY.

25 AS THAT PROCEEDING WAS GOING ON DU PONT DECIDED THAT

10

1 IT, TOO, WANTED TO GET THE VIEWS OF THE EXPERT AT THE PATENT
2 OFFICE. SO IT, TOO, FILED THE RE-EXAMINATION REQUEST. IN THAT
3 REQUEST DU PONT WAS ENTITLED TO FILE WHATEVER PRINTED ART IT
4 WANTED. IT CHOSE WHAT IT WANTED TO FILE AND IT CHOSE WHAT IT
5 WANTED THE PATENT OFFICE TO RULE ON.

6 IT CHOSE NOT THE NSF GRANT PROPOSAL THAT DU PONT WILL
7 BE PUTTING IN EVIDENCE IN THIS LAWSUIT, IT CHOSE ANOTHER GRANT
8 DOCUMENT. DOCTOR KHORANA'S LABORATORY AND THE PATENT OFFICE
9 SAID THE OTHER GRANT DOCUMENT DOESN'T INVALIDATE THE PATENT, BUT
10 THE PARTICULAR ONE THAT'S INVOLVED IN THIS SUIT WAS NOT PUT
11 BEFORE THE PATENT OFFICE BY DU PONT.

12 IT ALSO WASN'T PUT BEFORE THE PATENT OFFICE BY
13 HOFFMAN-LA ROCHE BECAUSE IT WASN'T PART OF THE ISSUES IN THIS
14 LAWSUIT AT THE TIME THAT HOFFMAN-LA ROCHE WENT TO THE PATENT
15 OFFICE AND SAID THESE ARE THE PRINTED PUBLICATIONS THAT DU PONT
16 IS ARGUING INVALIDATE THE PATENT.

17 NOW, IN THE FIRST STEP IN THE PATENT OFFICE THE PATENT
18 EXAMINER LOOKS AT THE NEW MATERIAL THAT'S SUBMITTED. IN THE
19 FIRST STEP IS FOR THE PATENT EXAMINER TO ASK IS THERE ANY
20 SUBSTANTIAL LIKELYHOOD THAT A REASONABLE PATENT EXAMINER COULD
21 FIND THAT THIS MATERIAL WOULD HAVE AN EFFECT ON THE VALIDITY OF
22 THESE PATENT CLAIMS.

23 AND THE THEORY APPARENTLY IS, IF IT DOESN'T PASS THAT
24 TEST, NO REASONABLE PATENT EXAMINER COULD THINK THEY WERE
25 MATERIAL THEY'RE NOT GOING TO GO WITH IT AND REQUIRE A STATEMENT

10

1 FROM THE PATENT OWNER IN OTHER PROCEEDINGS. YOU'LL HEAR THAT IN
2 THE HOFFMAN-LA ROCHE PROCEEDING AND IN THE DU PONT PROCEEDING.

3 AT THIS VERY FIRST STEP THE ONLY QUESTION IS COULD ANY
4 REASONABLE EXAMINER THINK THIS, MOST OF DU PONT'S ARGUMENTS WERE
5 THROWN OUT. INCLUDED IN THE STUFF THAT WAS THROWN OUT WAS EVERY
6 SINGLE ARGUMENT IT WOULD HAVE BEEN OBVIOUS TO ONE ORDINARILY
7 SKILLED IN THE ART, BASED UPON THE KHORANA PUBLICATIONS TO DO
8 PCR. THEY WERE THROWN OUT AT THIS VERY FIRST STAGE BY THE
9 EXPERTS IN THE PATENT OFFICE.

10 NOW, AFTER THIS FIRST STAGE CETUS WAS ENTITLED TO FILE
11 ITS PATENT OWNERS STATEMENT AND IT FILED ONE, IT FILED IT IN THE
12 HOFFMAN-LA ROCHE PROCEEDING. BY THE TIME THE DU PONT PROCEEDING
13 HAD GOTTEN TO THE POINT WHERE CETUS COULD FILE ONE, THE TWO WERE
14 IDENTICAL. THE PATENT EXAMINER HAD SAID THEY WERE THE SAME.
15 BECAUSE THEY WERE THE SAME THERE WAS OBVIOUSLY NO POINT IN
16 FILING A SECOND IDENTICAL PATENT OWNERS STATEMENT AT THIS POINT
17 TO MAKE SURE THE RELEVANT ARGUMENTS WERE ALL PUT TOGETHER AND
18 DECIDED AT ONCE.

19 CETUS ASKED THE TWO PROCEEDINGS BE COMBINED THAT
20 INSURED IN DECIDING THE HOFFMAN LA ROCHE PROCEEDING ALL THE DU
21 PONT ARGUMENTS WOULD BE CONSIDERED, ALL THE MATERIAL DU PONT PUT
22 BEFORE THE PATENT OFFICE WOULD BE CONSIDERED. THERE INCLUDED
23 THE VARIOUS PUBLICATIONS, SOME PATENTS, THE GRANT DOCUMENT THEY
24 CHOSE AT THAT TIME AND ALSO SOME WRITTEN TESTIMONY FROM SOME
25 SCIENTISTS THAT IT RECRUITED.

11

1 ONE OF THOSE SCIENTISTS WAS DOCTOR SAMBROOK, THE MAN
2 WHO WROTE THE PREFACE TO THE BOOK WE LOOKED AT A MOMENT AGO.
3 THE OTHER IS DOCTOR ARTHUR KORNBERG THE STANFORD SCIENTISTS WHO
4 MR. FIGG HAS INDICATED IS GOING TO BE TESTIFYING HERE AT TRIAL.

5 SO THE PATENT OFFICE LOOKED AT ALL OF THIS, INCLUDING
6 THE TESTIMONY FROM THE SCIENTISTS THAT DU PONT PUT BEFORE IT AND
7 THE PATENT EXAMINER DECIDED NONE OF THIS MATTERS, THE PATENTS
8 ARE STILL VALID.

9 SO THE PATENT OFFICE ISSUED WHAT ARE CALLED
10 RE-EXAMINATION CERTIFICATES. THESE RE-EXAMINATION CERTIFICATES
11 DO TWO THINGS THAT ARE IMPORTANT FOR WHAT I'M TALKING ABOUT
12 RIGHT NOW:

13 FIRST, THEY LIST THE SPECIFIC ART THAT THE PATENT
14 OFFICE HAS CONSIDERED. HERE YOU SEE THERE'S THE KLEPPE ARTICLE,
15 HERE'S THE THE ARTICLE AND HERE'S THE VARIOUS OTHER PIECES OF
16 ART THAT DU PONT CHOSE TO DECIDE AT THAT TIME.

17 THERE'S ALSO ANOTHER ARTICLE BY DOCTOR KHORANA WHICH
18 WAS INVOLVED BACK THEN. BASED UPON ALL OF THAT THE PATENT
19 EXAMINER IN THE PATENT OFFICE DECIDED THAT ALL OF THE CLAIMS ARE
20 CONFIRMED. HERE IT'S ONE THROUGH 26 AND THERE ARE 26 CLAIMS.

21 NOW, THE PATENT OFFICE DIDN'T JUST HAVE DOCTOR
22 MARTINELL EXPERT EXAMINER LOOK AT THIS. YOU'LL HEAR THAT IN
23 ADDITION DOCTOR MARTINELL'S SUPERVISOR LOOKED AT IT AND HE, TOO,
24 SIGNED THE DECISION WHICH LED TO THE ISSUANCE OF THESE
25 CERTIFICATES.

11 1 YOU'LL HAVE A CHANCE TO SEE THE OPINIONS OF THE PATENT
2 EXAMINER AND HIS SUPERVISOR AND THEIR DETAILED EXPLANATIONS AND
3 TECHNICAL TERMS OF WHY IT IS THAT THE ART FROM THE KHORANA
4 LABORATORY JUST DOESN'T EQUAL PCR.

5 IN GENERAL WHAT YOU'LL HEAR THEM SAY IS THAT THE
6 MATERIAL FROM THE KHORANA LABORATORY IS VAGUE, GENERAL AND IT'S
7 IMPOSSIBLE TO TELL FROM IT EXACTLY WHAT WAS DONE. BUT IT
8 CERTAINLY ISN'T POSSIBLE TO USE THAT TO DO PCR. IT WOULD NOT
9 HAVE BEEN POSSIBLE FOR ONE ORDINARILY SKILLED IN THE ART TO HAVE
10 USED THAT VAGUE AMBIGUOUS LANGUAGE IN THOSE ARTICLES TO DO PCR
11 BACK AT THE TIME IN 1984 WHEN CETUS MADE ITS INVENTION.

12 NOW, IT'S ALSO TRUE YOU'LL HEAR THAT THE PATENT OFFICE
13 DID NOT CONSIDER THE EXPERIMENTS THAT WERE DONE AND WERE NEVER
14 PUT INTO ANY PUBLICATION. THESE WERE THE EXPERIMENTS THAT WERE
15 DONE FIRST BY DOCTOR KLEPPE AND THEN BY DOCTOR MOLINEUX.
16 EXPERIMENTS DOCTOR KHORANA AND HIS COLLEAGUES DECIDED DIDN'T
17 MERIT PUBLICATION. THAT THEY DIDN'T COME UP TO THE STANDARDS OF
18 RELIABILITY, ACCURACY, REPRODUCIBILITY TO BE PUBLISHABLE
19 EXPERIMENTS. SO IN ADDITION TO THE PRINTED MATERIAL DU PONT
20 WILL PRESENT EVIDENCE OF THESE EXPERIMENTS. IT'S TRUE THE
21 PATENT OFFICE DID NOT CONSIDER THEM.

22 WHAT YOU'RE GOING TO SEE IS THAT THE EVIDENCE OF THESE
23 EXPERIMENTS CERTAINLY NO MORE COMPELLING THAN THE DESCRIPTIONS
24 IN THESE ARTICLES AS EVIDENCE THAT PCR WAS EVER DONE IN DOCTOR
25 KHORANA'S LABORATORY.

11

1 LIKE DU PONT, IN ADDITION TO THE REAL WORLD EVIDENCE
2 WE'LL BE PRESENTING TO YOU, WE WILL BE PRESENTING SOME EXPERT
3 WITNESSES. SOME WITNESSES WHO WILL COME TO YOU, REVIEW THE
4 ARTICLES, REVIEW THE EXPERIMENTS AND TELL YOU WHAT THEY MEAN AND
5 WHAT THEY DON'T MEAN.

6 ONE OF THESE SCIENTISTS IS A VERY SPECIAL PERSON.
7 THERE'S AS LABORATORY IN ENGLAND THAT IS, IF YOU WILL, THE BIRTH
8 PLACE OF BIOTECHNOLOGY. IT IS AT THIS LABORATORY IN ENGLAND
9 CAMBRIDGE WHERE DOCTOR WATSON AND DOCTOR KLUG FIGURED OUT THE
10 STRUCTURE OF DNA.

11 THEY FIGURED OUT IT HAD THESE BUILDING BLOCKS THAT FIT
12 TOGETHER. THEY FIGURED OUT THE BASE PAIRING. THEY FIGURED OUT
13 IT ACTUALLY WRAPS AROUND ITSELF IN A HELICAL STRUCTURE.

14 THIS LABORATORY HAS AMONG ITS ALUMNI A SERIES OF PEOPLE
15 WHO WERE AWARDED NOBEL PRIZES FOR THE WORK THEY DID THERE. IT'S
16 THE MOST IMPORTANT BIOTECHNOLOGY LABORATORY IN THE WORLD WITHOUT
17 DOUBT. THE HEAD OF THIS LABORATORY IS A SCIENTIST NAMED SIR
18 AARON KLUG. HE'S ONE OF THE MANY NOBEL PRIZE WINNERS FROM THE
19 LABORATORY.

12

20 DR. KLUG'S TESTIMONY WILL BE PRESENTED TO YOU. DOCTOR
21 KLUG'S HEALTH DIDN'T ALLOW HIM TO COME TO SAN FRANCISCO, SO ONE
22 OF THE DU PONT LAWYERS, ONE OF MR. FIGG'S PARTNERS AND I
23 TRAVELED TO CAMBRIDGE TO GET HIS TESTIMONY. AND WE DID THE
24 USUAL QUESTION AND ANSWER FORMAT. IT WAS ALL WRITTEN DOWN AND
25 WE'LL HAVE A CHANCE TO READ THAT TO YOU.

12 1 ANOTHER OF THE SCIENTISTS WHO WILL BE PRESENTING IS DR.
2 JAMES DAHLBERG. DR. DAHLBERG IS A PROFESSOR AT THE UNIVERSITY
3 OF WISCONSIN, A MAN WHO HAS BEEN CHOSEN BY HIS PEERS TO LEAD
4 VARIOUS CONFERENCES IN THE BIOTECHNOLOGY FIELD. HE'S A
5 SCIENTIST WHO USED TO COLLABORATE WITH DR. KHORANA.

6 IN FACT, YOU'LL SEE DR. KHORANA SAYS THAT THE PRINCIPLE
7 BEHIND REPLICATION REACTIONS IS A PRINCIPLE THAT WAS BEING USED
8 OR WAS BEING USED IN THE WORK THAT DR. DAHLBERG WAS DOING.

9 DR. DAHLBERG WILL BE HERE AND HE WILL ANALYZE FOR YOU
10 IN DETAIL THE EXPERIMENTS THAT WERE DONE AND THE EVIDENCE OF
11 THOSE EXPERIMENTS THAT YOU'LL SEE.

12 WHAT THESE SCIENTISTS, DR. KLUG, DR. DAHLBERG AND SOME
13 OTHERS, WILL TELL YOU WILL BE CLEAR AND UNEQUIVOCAL AND IT WILL
14 BE THIS: DR. MULLIS INVENTED PCR. THEY'LL TELL YOU THAT PCR
15 WAS NOT OBVIOUS AT THE TIME THAT IT WAS INVENTED BY DR. MULLIS
16 IN 1984.

17 THEY'LL TELL YOU THAT THIS WORK THAT WAS DONE IN DR.
18 KHORANA'S LABORATORY, WHETHER IT'S REFLECTED IN ARTICLES,
19 LETTERS, OR WHETHER IT'S REFLECTED IN THE EVIDENCE WE HAVE IN
20 THE EXPERIMENTS, DOES NOT SHOW PCR WAS DONE AND COULD NOT HAVE
21 BEEN USED BY SCIENTISTS IN 1984 OR ANY OTHER TIME TO FIGURE OUT
22 HOW TO DO PCR.

23 INDEED YOU'LL HEAR FROM THE SCIENTISTS THAT THE DU PONT
24 ARGUMENTS ARE BASED UPON GROSSLY OVERSIMPLIFYING PCR AND WHAT IT
25 TAKES TO MAKE PCR WORK. THERE ARE MANY PROBLEMS THEY'LL TELL

12

1 YOU THAT WOULD HAVE PREVENTED ANYONE FROM JUST SITTING DOWN WITH
2 THE KIND OF VAGUE THINGS IN THESE ARTICLES AND TRYING TO DO PCR.

3 THE PROBLEMS IN FACT WERE REASONABLY WELL-KNOWN. THEY
4 HAVE TECHNICAL TERMS LIKE PRIMER, STRAND SWITCHING. THEY HAD
5 PROBLEMS RE ANNEALING OF COMPLIMENTARY STRANDS, THINGS LIKE
6 THAT, THINGS WE WILL SHOW YOU THROUGH OUR SCIENTISTS IN WHAT WE
7 HOPE WILL BE A CLEAR AND SIMPLE EXPLANATION.

8 WHILE THE PROBLEMS WERE WELL-KNOWN, THE SOLUTIONS WERE
9 NOT KNOWN. THEY WEREN'T KNOWN UNTIL THEY WERE EXPLAINED BY DR.
10 MULLIS AND EXPLAINED FIRST IN THE PRINTED PUBLICATION IN THE
11 DECEMBER 1985 ARTICLES, THEN EXPLAINED IN MORE DETAIL IN THE
12 PATENTS THAT ARE IN YOUR BOOK.

13 ONE LAST POINT ABOUT THIS WORK FROM DOCTOR KHORANA'S
14 LABORATORY, THEN I'M ALMOST DONE. THAT POINT IS THIS: THE
15 EVIDENCE THAT WILL BE PUT BEFORE YOU WHAT HAPPENED IN DR.
16 KHORANA'S LABORATORY IS VERY INCOMPLETE. IT'S INCOMPLETE
17 THROUGH NO FAULT OF ANYONE REALLY, BUT IT IS INCOMPLETE.

18 THE NOTEBOOKS OF DR. MULLIS WHICH WOULD HAVE SHOWN THE
19 DETAILS OF WHAT HE DID ARE JUST GONE. NO ONE KNOWS WHAT
20 HAPPENED TO THEM. SO THERE ARE NO DETAILED RECORDS OF DR.
21 MULLIS NEW WORK AT ALL.

22 DR. KLEPPE, AS MR. FIGG POINTED OUT, UNFORTUNATELY DIED
23 A COUPLE OF YEARS AGO. DR. KHORANA HAS CHOSEN NOT TO TESTIFY,
24 SO WE WON'T HAVE THE BENEFIT OF HIS RECOLLECTION AND VIEWS ON
25 THESE SUBJECTS.

12 1 THIS INCOMPLETE RECORD IS NOT GOING TO PRESENT ANY
2 CLEAR AND CONVINCING EVIDENCE THE EXPERIMENTS DONE IN THAT
3 LABORATORY CONSTITUTED PCR. WHAT YOU ARE GOING TO SEE AS TO THE
4 GRANT PROPOSALS IS THAT THERE WERE A SERIES OF REPORTS BY DR.
5 KHORANA TO THE GOVERNMENT ABOUT HIS WORK.

6 YOU WILL SEE THAT IN NONE OF THOSE REPORTS DR. KHORANA
7 EVER CLAIMED I HAVE SUCCESSFULLY ACHIEVED REPAIR REPLICATION PCR
8 OR ANY OF THESE OTHER COPYING METHODS. HE AT VARIOUS TIMES SAYS
9 I HAVE THIS PROPOSAL OR THIS MIGHT WORK, AND EXPERIMENTS ARE IN
10 PROGRESS THAT WE'RE WORKING ON.

11 ALL OF THIS ENDS YOU'LL SEE IN 1985 WHEN DR. KHORANA
12 REPORTED TO THE GOVERNMENT THAT HIS EFFORTS TO CREATE THIS
13 METHOD AND MAKE IT WORK HAD FAILED. HE TOLD THE GOVERNMENT THAT
14 IT HAD PROVEN TO BE IMPOSSIBLE TO GET EITHER EXTENSIVE OR
15 COMPLETE COPIES OF THE DNA HE WAS TRYING TO MAKE COPIES OF.

16 OBVIOUSLY, IF HIS METHOD DIDN'T MAKE A COMPLETE COPY IT
17 WAS WORTHLESS BECAUSE THE PARTIAL COPY COULDN'T BE USED IN PLACE
18 OF THE ORIGINAL. DR. KHORANA HIMSELF REPORTED TO THE GOVERNMENT
19 IN 1975 THAT HE WAS UNABLE TO MAKE COMPLETE COPIES AND THAT'S
20 THE LAST THING HE SAID ABOUT USING THE REPAIR REPLICATION AS A
21 COPYING METHOD.

22 WHEN A FEW WEEKS FROM NOW WE CONCLUDE, YOU HAVE SEEN NO
23 EVIDENCE THAT JUSTIFIES TAKING THE REMARKABLE DISCOVERY OF PCR
24 FROM DR. MULLIS. YOU WILL SEE NO EVIDENCE THAT SHOWS YOU
25 CLEARLY AND CONVINCINGLY OR SHOWS YOU AT ALL DR. MARTINELL AND

13
1 HIS COLLEAGUES AT THE PATENT OFFICE EITHER IN GRANTING THE
2 PATENT OR RECONFIRMING THE PATENT WHEN THEY WERE ASKED TO LOOK
3 AT IT AGAIN BY DU PONT LAST YEAR. YOU'LL SEE NO EVIDENCE ON THE
4 BASIS OF WHICH YOU WOULD INVALIDATE THESE PATENTS OR ANY OF
5 THEIR CLAIMS.

6 THE COURT: THANK YOU, MR. PASAHOW. I THINK WE HAVE
7 TEN MINUTES LEFT. HARDLY ENOUGH TIME TO GET ANY TESTIMONY IN;
8 IS THAT RIGHT?

9 WE HAVE A FEW OTHER MATTERS WE CAN TAKE UP IN ANY
10 EVENT.

11 LADIES AND GENTLEMEN, WE'LL RECESS FOR THE DAY AND WE
12 RECONVENE TOMORROW MORNING AT 8:00 O'CLOCK AND THAT'S WHEN WE
13 WILL BEGIN HEARING THE TESTIMONY OF WITNESSES IN THIS CASE.

14 PLEASE FOLLOW THE INSTRUCTIONS THAT I'VE GIVEN YOU. MY
15 CLERK HAS JUST CALLED TO MY ATTENTION THE FACT THAT INDEED I
16 GUESS THERE MAY BE SOME THINGS IN THE LOCAL PRESS. I TRUST NOT
17 EVERY DAY, BUT WHO KNOWS.

18 IN ANY EVENT, YOU ARE NOT TO READ ANYTHING ABOUT THE
19 CASE, SO YOU SEE A HEADLINE THAT LOOKS LIKE IT HAS SOME
20 RELATIONSHIP TO THIS CASE JUST IGNORE IT AND READ SOMETHING
21 ELSE.

22 OKAY. THANK YOU. HAVE A VERY PLEASANT AFTERNOON AND
23 EVENING. SEE YOU TOMORROW MORNING AT 8:00 O'CLOCK.

24 (PROCEEDINGS HELD IN OPEN COURT, JURY NOT PRESENT:)

25 THE COURT: WHO ARE YOU GOING TO BE CALLING TOMORROW?

13

1 MR. FIGG: OUR FIRST WITNESS WILL BE MR. DE GRANDI.

2 THE COURT: THEN?

3 MR. FIGG: AFTER THAT DR. KORNBERG.

4 THE COURT: ABOUT HOW LONG DO YOU EXPECT MR. DE GRANDI
5 WILL BE?

6 MR. FIGG: I THINK HIS DIRECT EXAMINATION WILL PROBABLY
7 TWO AND A HALF HOURS, SOMETHING ALONG THAT LINE.

8 THE COURT: OKAY. ANYTHING ELSE WE NEED TO TAKE CARE
9 OF TODAY?

10 MR. LEWIS: YOUR HONOR, I WOULD LIKE A POINT OF
11 CLARIFICATION IN CONNECTION WITH MR. DE GRANDI'S TESTIMONY. AT
12 THE PRETRIAL CONFERENCE IN NOVEMBER I THOUGHT YOU HAD INDICATED
13 THERE SHOULD NOT BE ANY TESTIMONY ABOUT PATENT MONOPOLIES, ANY
14 COMPETITIVE EFFECTS. MR. FIGG'S OPENING IT SOUNDED LIKE THAT
15 MIGHT BE PART OF THE PLAN. IT WOULD HELP IF WE CAN CLARIFY
16 THAT.

17 MR. FIGG: I DON'T REMEMBER THAT AT ALL, YOUR HONOR.
18 YOU SIMPLY INDICATED THAT -- I DON'T REMEMBER --

19 THE COURT: I DON'T KNOW WHAT THE RELEVANCY OF THAT, IN
20 ANY EVENT. THE QUESTION IS THE VALIDITY OF THE PATENTS. WHAT
21 EFFECT IT MAY HAVE IF SOMEONE HAS A PATENT, WHAT THE COMMERCIAL
22 EFFECT MAY BE OR THE FINANCIAL IMPACT MAY BE IS REALLY NOT
23 RELEVANT.

24 MR. FIGG: NO. OUR POINT IS SIMPLY TO POINT OUT THE
25 BREADTH OF THE CLAIMS IS WHAT DEFINES SCOPE OF THE PATENT AND

13 1 THE EFFECT OF THE PRIOR ART ON THE PATENT WHICH WE WILL DO
2 THROUGH MR. DE GRANDI'S TESTIMONY.

3 I THINK WHAT MR. LEWIS MIGHT BE TALKING ABOUT WE SPOKE
4 ABOUT PRESENTING MR. QUISENBERRY AS A WITNESS. WE HAVE DROPPED
5 HIM FROM OUR WITNESS LIST NOW.

6 THE COURT: WELL, AS LONG AS WE UNDERSTAND THAT THE
7 COMPETITIVE OR ANTICOMPETITIVE EFFECT IMPACT ON THE PATENT
8 REALLY IS NOT AN ISSUE, IS NOT RELEVANT TO THE ISSUES HERE.

9 I'M SOMEWHAT CONCERNED, SO FAR YOU'VE BEEN CAREFUL WHEN
10 YOU'VE BEEN TALKING ABOUT THE SCOPE OR THE BREADTH OF THE CLAIMS
11 TO TIE IT UP WITH THE PRIOR ART, AND I ASSUME OPPOSING COUNSEL
12 IS GOING TO BE ON THEIR GUARD WITH RESPECT TO SNEAKING IN 112,
13 SECTION 112 MATERIAL, BUT IT'S GOING TO HAVE TO BE CONNECTED TO
14 THE PRIOR ART. YOU UNDERSTAND THAT GIVEN THE COURT'S EARLIER
15 RULING?

16 MR. FIGG: YES. WE'RE NOT GOING TO TALK ABOUT 112
17 EXCEPT INSOFAR AS THAT WAS INVOLVED IN THE PROSECUTION OF THE
18 PATENT.

19 THE COURT: YOU WOULDN'T BE THE FIRST LAWYER TO TRY TO
20 SNEAK SOMETHING IN BY THE BACK DOOR.

21 MR. LEWIS: I'LL BE ON MY TOES, YOUR HONOR.

22 THE COURT: OKAY. THERE IS ONE RULE SINCE WE HAVE A
23 HOST OF ATTORNEYS HERE, THAT IS THAT THERE'S NO DOUBLE-TEAMING.
24 WHOEVER IS GOING TO EXAMINE A WITNESS EXAMINES THAT WITNESS AND
25 WHOEVER IS GOING TO CROSS-EXAMINE IS THE ONE TO ASSERT ANY

14
1 OBJECTIONS. SO IF THE WRONG COUNSEL ASSERTS AN OBJECTION YOU
2 MAY FIND YOURSELF CROSS-EXAMINING A WITNESS YOU WEREN'T PREPARED
3 FOR. SO JUST KEEP THAT IN MIND. OKAY.

4 MR. LEWIS: APPRECIATE THE WARNING, YOUR HONOR.

5 THE COURT: ANYTHING SO YOU RESTRAIN YOURSELF IN CASE
6 YOUR CO-COUNSEL FAILS TO OBJECT YOU THINK HE OR SHE SHOULD HAVE.

7 ANYTHING ELSE I SHOULD BE AWARE OF?

8 PROBABLY A LOT OF I SHOULD BE AWARE OF. ANYTHING I
9 NEED TO KNOW BEFORE TOMORROW FOR THIS CASE?

10 MR. LEWIS: I DON'T THINK SO, YOUR HONOR. WE WILL --
11 LET'S SEE, IF YOU'RE GOING TO PUT DR. KORNBERG ON, MR. FIGG, WE
12 WILL NEED TO BE MOVING IN THE NEW EQUIPMENT TODAY. WILL WE HAVE
13 ACCESS LATE THIS AFTERNOON OR CAN WE ARRANGE --

14 THE COURT: YES, CERTAINLY. I THINK WE HAVE JUST ONE
15 SHORT PROCEEDING IN HERE THIS AFTERNOON, SO WE'RE ALL RIGHT.
16 AND EVEN DURING THAT I DON'T THINK THERE WILL BE A PROBLEM IF
17 YOU NEED TO GET IN.

18 WERE YOU ABLE TO LOCATE THE COPY OF THE ORDER?
19 APPARENTLY THERE WAS SOME PROBLEM ABOUT THE COPY OF THE ORDER.

20 MR. KURZ: WE WERE LOOKING FOR THAT AND WE GOT IT FROM
21 OPPOSING COUNSEL.

22 THE COURT: FINE. ALSO, DID YOU HAVE ANY OBJECTIONS TO
23 DU PONT'S DESIGNATIONS OF ANY PORTION OF DOCTOR KLUG'S
24 DEPOSITION?

25 MR. LEWIS: LET ME JUST CLARIFY THAT. NO, THERE ARE